News for OTIC Stock

Otonomy Announces Change in Stock Exchange Listing Otonomy Provides Corporate Update Otonomy Reports Third Quarter 2022 Financial Results and Provides Corporate Update Otonomy Reports Results from Clinical Evaluation of OTO-413 Higher Doses in Patients with Hearing Loss Otonomy Reports Results from Phase 2 Clinical Trial of OTO-313 in Patients with Tinnitus Otonomy Reports Second Quarter 2022 Financial Results and Provides Corporate Update Otonomy to Report Second Quarter 2022 Financial Results and Provide Corporate Update Otonomy to Participate in the H.C. Wainwright Global Investment Conference Otonomy Announces OTO-825 Presentation at the American Society of Gene & Cell Therapy Annual Meeting Otonomy Reports First Quarter 2022 Financial Results and Provides Corporate Update Otonomy to Report First Quarter 2022 Financial Results and Provide Corporate Update Otonomy Reports Positive Top-Line Results from Phase 2a Clinical Trial of OTO-413 in Patients with Hearing Loss Otonomy to Host Virtual Investor R&D Event on March 22, 2022 Otonomy Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update Otonomy to Participate in Two Upcoming Investor Conferences Otonomy to Host Virtual Investor R&D Event on March 22, 2022 Otonomy Completes Enrollment in Phase 2 Clinical Trial of OTO-313 in Tinnitus Otonomy to Report Fourth Quarter and Full Year 2021 Financial Results and Provide Corporate Update Otonomy Announces OTO-413 Presentations at American Auditory Society Annual Meeting Otonomy Announces Multiple Presentations at Association for Research in Otolaryngology Annual Meeting Otonomy Reports Corporate and Product Pipeline Update Otonomy to Participate in the H.C. Wainwright BioConnect Conference Otonomy to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference Otonomy Reports Third Quarter 2021 Financial Results and Provides Corporate Update Otonomy to Report Third Quarter 2021 Financial Results and Provide Corporate Update Otonomy Announces Multiple Presentations at Neuroscience 2021 Meeting Otonomy Announces Publication of Phase 1/2 Trial Results Showing Tinnitus Improvement in Patients Receiving OTO-313 Otonomy Announces Presentation of OTO-413 Clinical Results at AAO-HNS Annual Meeting Otonomy to Participate in Two Upcoming Investor Conferences Otonomy Appoints Jill Broadfoot to Board of Directors Otonomy Reports Second Quarter 2021 Financial Results and Provides Corporate Update Otonomy to Report Second Quarter 2021 Financial Results and Provide Corporate Update Otonomy Initiates Expansion of Phase 1/2 Clinical Trial for OTO-413 in Hearing Loss Otonomy and AGTC Present Preclinical Proof-of-Concept Results for OTO-825 Gene Therapy at ASGCT Annual Meeting Otonomy Reports First Quarter 2021 Financial Results and Provides Corporate Update Otonomy to Report First Quarter 2021 Financial Results and Provide Corporate Update Otonomy and AGTC to Present Preclinical Proof-of-Concept Results for OTO-825 Gene Therapy at ASGCT Annual Meeting Otonomy Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares Otonomy Announces Pricing of $30.1 Million Public Offering Otonomy Announces Proposed Public Offering Otonomy to Present at the Needham Virtual Healthcare Conference Otonomy Announces Presentation of OTO-313 Clinical Results at American Neurotology Society Annual Meeting Otonomy Initiates Phase 2 Clinical Trial of OTO-313 in Tinnitus Otonomy to Participate in Three Upcoming Investor Conferences Otonomy Announces Top-Line Results for the Phase 3 Clinical Trial of OTIVIDEX® in Patients with Ménière's Disease Otonomy Announces Multiple Presentations at Association for Research in Otolaryngology Annual Meeting Otonomy Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update Otonomy to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Corporate Update Otonomy to Participate in the H.C. Wainwright BioConnect 2021 Virtual Conference Otonomy Reports Positive Top-Line Results from Phase 1/2 Clinical Trial of OTO-413 in Patients with Hearing Loss Otonomy Provides Update on OTIVIDEX® and OTO-313 Programs Otonomy to Participate in Two Upcoming Investor Conferences Otonomy Reports Third Quarter 2020 Financial Results and Provides Corporate Update Otonomy to Report Third Quarter 2020 Financial Results and Provide Corporate Update Otonomy Completes Patient Enrollment for Phase 3 Trial of OTIVIDEX® in Ménière’s Disease Otonomy to Participate in Four Upcoming Investor Conferences Otonomy Reports Second Quarter 2020 Financial Results and Provides Corporate Update Otonomy Provides Update on OTIVIDEX® Program Otonomy to Present at Raymond James 2020 Human Health Innovation Conference Otonomy to Host Pipeline Program Update Conference Call and Webcast Otonomy to Report Second Quarter 2020 Financial Results and Provide Corporate Update Otonomy Announces Pricing of $60.1 Million Public Offering Otonomy Reports Positive Top-Line Results from Phase 1/2 Clinical Trial of OTO-313 in Patients with Tinnitus Otonomy Provides Update on Clinical Trials and Development Programs Otonomy to Hold Virtual Annual Meeting of Stockholders for 2020 Otonomy Reports First Quarter 2020 Financial Results and Provides Corporate Update Otonomy Announces Exclusive License Agreement with Kyorin for Novel Compound in OTO-6XX Hearing Loss Program Otonomy Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares Otonomy Announces Proposed Public Offering